Vector Genome Identity

Executive Summary

Vector Genome Identity confirms that the packaged therapeutic genome has the correct nucleotide sequence. This is a foundational Critical Quality Attribute (CQA) because the genome encodes the therapeutic protein. Even a single base pair error can compromise efficacy or introduce safety risks through altered or nonfunctional protein expression. Therefore, confirming that the packaged genome sequence is 100% accurate is a fundamental requirement for gene therapy quality control.

Category: Identity

Criticality: Critical Quality Attribute (CQA)

Stability Indicating: Yes

Typical Reporting/Limits:

Reportable Value: The confirmed nucleotide sequence of the vector genome or designated critical regions (e.g., transgene cassette).
Common Units: Not applicable; results are qualitative (identity-based).
Typical Acceptance Criteria: 1100% sequence identity to the reference transgene sequence, confirmed by exact match in Sanger sequencing for release testing.

Analytical Procedures

Context in Practice: Example Specifications

From Specification: Typical AAV Drug Product Specifications

Rationale: Confirm intended transgene cassette.
Acceptance Criteria: Sequence matches reference; variant frequencies within predefined thresholds. Restriction map matches expected pattern.
Orthogonal Method(s): Next-Generation Sequencing (NGS), Restriction Enzyme Mapping

Key Analytical Challenges

ITR Sequencing: AAV inverted terminal repeats (ITRs) are GC-rich, form strong hairpin structures, and are refractory to Sanger and short-read sequencing. Long-read platforms (e.g., PacBio) are often required to confirm their integrity.
Variant vs. Artifact: Distinguishing true low-frequency variants from artifacts introduced during PCR or sequencing requires deep coverage and robust bioinformatic pipelines.
Representative Sampling: Ensuring the extracted DNA represents the full packaged population is essential for meaningful identity testing and variant detection.

Phase-Appropriate CMC & Regulatory Expectations

Early Phase (Phase 1–2): A qualified Sanger sequencing method is typically used to confirm the transgene sequence in the vector and critical starting materials (e.g., plasmids).
Late Phase & BLA: In late-phase and BLA submissions, regulators expect full-vector sequencing, including ITRs. Long-read NGS is typically used, with validated Sanger sequencing retained for routine lot release identity testing.

Risk Assessment

Patient Risk (Efficacy & Safety):
- Loss of efficacy due to incorrect or truncated protein expression
- Safety concerns from novel or immunogenic proteins caused by sequence errors
Product Risk (Consistency):
- Incorrect ITRs can impair genome replication and packaging, reducing yield and product consistency.

Relationship to Other Attributes

Potency: Correct genome identity is a prerequisite for correct transgene expression and functional protein production.
Purity & Impurities: Sequence variants or truncated genomes represent product-related impurities.
Full/Empty Capsid Ratio: Genome integrity, particularly of the ITRs, is essential for efficient packaging, which directly impacts the full-to-empty ratio.

Industry Commentary & Standards

Sanger sequencing is widely used for high-accuracy identity confirmation in routine QC, while next-generation sequencing (e.g., PacBio) provides comprehensive genome characterization, including ITRs, for development and regulatory submissions.

Key Guideline Commentary

ICH Q6B: Requires proof of primary structure. For gene therapy, this principle extends to the nucleotide sequence of the therapeutic vector genome.
FDA Gene Therapy CMC Guidance (2020): Establishes clear expectations for full-vector characterization, including complete genome sequencing and confirmation of identity.